药价监管的法治问题研究
Research on the legal issues of drug price supervision
牟霞 1羊海燕1
作者信息
- 1. 西南医科大学法学院 四川 泸州市 646600
- 折叠
摘要
3年疫情之后,民众已然成为健康的第一责任人,保障药品的可及性与可负担性是提升民众健康的刚性需求.以降低药价、保障人民群众药品可及性以及可负担性的药价改革措施频繁进行,但是改革实效却始终与药价改革预期目标存在差距,与之配套的《药品管理法》并未从根源上解决药价监管问题.根本原因是现存法律制度忽视了药品价格监管困境的根源在于信息不对称.以准公共产品理论剖析药品的特殊性,为药品价格有别于普通商品的监管提供正当性和合法性,以"委托-代理"分析药品市场信息不对称现状,从根本上解决药价监管的难点与痛点,为扎实推进"健康中国"的"最后一公里"提供支撑.
Abstract
After three years of epidemics,people have become the first responsible for their health,and the guarantee of accessibility and affordability of medicines is a rigid demand to improve people's health.The drug price reform measures to reduce drug prices and ensure the accessibility and affordability of drugs for the public have been carried out frequently,but the effectiveness of the reform has always been different from the expected goal of the drug price reform,and the Drug Administration Law has not solved the problem of drug price regulation from the root.The fundamental reason is that the existing legal system involves the neglect of the drug price regulation dilemma rooted in information asymmetry.This paper analyzed the special characteristics of drugs with the quasi-public product the-ory,provided legitimacy and legality for the regulation of drug prices different from ordinary commodities,analyzed the sta-tus quo of information asymmetry in the drug market with the"principal-agent",solved the difficulties and pain points in the regulation of drug prices at the root,and promoted the"last step"of Healthy China.
关键词
委托-代理/信息不对称/准公共产品/药价监管Key words
Principal-agent/Asymmetry information/Quasi public goods/Drug price regulation引用本文复制引用
基金项目
四川省哲学社会科学重点研究基地——四川医事卫生法治研究中心立项资助的项目(YF23-Q06)
泸州市哲学社会科学研究规划课题项目(LZ23A037)
出版年
2024
NETL
NSTL
万方数据